Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon

R. Cozzolongo, R. Cuppone, V. Giannuzzi, L. Amati, L. Caradonna, V. Tamborrino, E. Jirillo, O. G. Manghisi

Research output: Contribution to journalArticle

Abstract

Background: Up to 80% of hepatitis C patients are refractory to treatment with interferon-α. These patients are not likely to benefit from higher dosages or longer duration of interferon alone. The addition of ribavirin has been shown to improve the response rate in patients resistant to a previous course of interferon-α alone. Aim: To evaluate whether a sustained hepatitis C virus (HCV) RNA response could be obtained with combination therapy of interferon-α and ribavirin in patients who did not respond to or relapsed after a standard interferon-α treatment. Methods: A total of 73 patients, 59 non-responders and 14 relapsers after interferon-α alone, were treated with a combination of ribavirin (1000-1200 mg/day) and interferon-α (3 MU three times a week) for 24 weeks. Alanine aminotransferase levels and HCV RNA were checked for 24 weeks after completion of therapy. Results: At the end of the combination therapy, 36 patients (49%) showed alanine aminotransferase normalization and in 20 patients (27%), HCV RNA was undetectable in serum. At the end of the 24 weeks follow-up period, only 12 patients (16%) had a sustained response with serum negativity of HCV RNA. This response was significantly higher in relapsers than in non-responders: five (36%) vs. seven (12%) patients (P = 0.03), respectively. Adverse effects were restricted to flu-like symptoms and moderate haemolytic anaemia. Conclusions: Combination of interferon-α and ribavirin is quite limited, both in scope and efficacy, in HCV patients who had a non-response to monotherapy with interferon. Better results may be expected in relapsers, but larger studies are necessary.

Original languageEnglish
Pages (from-to)129-135
Number of pages7
JournalAlimentary Pharmacology and Therapeutics
Volume15
Issue number1
DOIs
Publication statusPublished - 2001

Fingerprint

Ribavirin
Chronic Hepatitis C
Interferon-alpha
Interferons
Hepacivirus
RNA
Therapeutics
Alanine Transaminase
Hemolytic Anemia
Hepatitis C
Serum

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon. / Cozzolongo, R.; Cuppone, R.; Giannuzzi, V.; Amati, L.; Caradonna, L.; Tamborrino, V.; Jirillo, E.; Manghisi, O. G.

In: Alimentary Pharmacology and Therapeutics, Vol. 15, No. 1, 2001, p. 129-135.

Research output: Contribution to journalArticle

Cozzolongo, R. ; Cuppone, R. ; Giannuzzi, V. ; Amati, L. ; Caradonna, L. ; Tamborrino, V. ; Jirillo, E. ; Manghisi, O. G. / Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon. In: Alimentary Pharmacology and Therapeutics. 2001 ; Vol. 15, No. 1. pp. 129-135.
@article{11b486dfdd2d4fa69c17b92e40ef688a,
title = "Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon",
abstract = "Background: Up to 80{\%} of hepatitis C patients are refractory to treatment with interferon-α. These patients are not likely to benefit from higher dosages or longer duration of interferon alone. The addition of ribavirin has been shown to improve the response rate in patients resistant to a previous course of interferon-α alone. Aim: To evaluate whether a sustained hepatitis C virus (HCV) RNA response could be obtained with combination therapy of interferon-α and ribavirin in patients who did not respond to or relapsed after a standard interferon-α treatment. Methods: A total of 73 patients, 59 non-responders and 14 relapsers after interferon-α alone, were treated with a combination of ribavirin (1000-1200 mg/day) and interferon-α (3 MU three times a week) for 24 weeks. Alanine aminotransferase levels and HCV RNA were checked for 24 weeks after completion of therapy. Results: At the end of the combination therapy, 36 patients (49{\%}) showed alanine aminotransferase normalization and in 20 patients (27{\%}), HCV RNA was undetectable in serum. At the end of the 24 weeks follow-up period, only 12 patients (16{\%}) had a sustained response with serum negativity of HCV RNA. This response was significantly higher in relapsers than in non-responders: five (36{\%}) vs. seven (12{\%}) patients (P = 0.03), respectively. Adverse effects were restricted to flu-like symptoms and moderate haemolytic anaemia. Conclusions: Combination of interferon-α and ribavirin is quite limited, both in scope and efficacy, in HCV patients who had a non-response to monotherapy with interferon. Better results may be expected in relapsers, but larger studies are necessary.",
author = "R. Cozzolongo and R. Cuppone and V. Giannuzzi and L. Amati and L. Caradonna and V. Tamborrino and E. Jirillo and Manghisi, {O. G.}",
year = "2001",
doi = "10.1046/j.1365-2036.2001.00893.x",
language = "English",
volume = "15",
pages = "129--135",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "1",

}

TY - JOUR

T1 - Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon

AU - Cozzolongo, R.

AU - Cuppone, R.

AU - Giannuzzi, V.

AU - Amati, L.

AU - Caradonna, L.

AU - Tamborrino, V.

AU - Jirillo, E.

AU - Manghisi, O. G.

PY - 2001

Y1 - 2001

N2 - Background: Up to 80% of hepatitis C patients are refractory to treatment with interferon-α. These patients are not likely to benefit from higher dosages or longer duration of interferon alone. The addition of ribavirin has been shown to improve the response rate in patients resistant to a previous course of interferon-α alone. Aim: To evaluate whether a sustained hepatitis C virus (HCV) RNA response could be obtained with combination therapy of interferon-α and ribavirin in patients who did not respond to or relapsed after a standard interferon-α treatment. Methods: A total of 73 patients, 59 non-responders and 14 relapsers after interferon-α alone, were treated with a combination of ribavirin (1000-1200 mg/day) and interferon-α (3 MU three times a week) for 24 weeks. Alanine aminotransferase levels and HCV RNA were checked for 24 weeks after completion of therapy. Results: At the end of the combination therapy, 36 patients (49%) showed alanine aminotransferase normalization and in 20 patients (27%), HCV RNA was undetectable in serum. At the end of the 24 weeks follow-up period, only 12 patients (16%) had a sustained response with serum negativity of HCV RNA. This response was significantly higher in relapsers than in non-responders: five (36%) vs. seven (12%) patients (P = 0.03), respectively. Adverse effects were restricted to flu-like symptoms and moderate haemolytic anaemia. Conclusions: Combination of interferon-α and ribavirin is quite limited, both in scope and efficacy, in HCV patients who had a non-response to monotherapy with interferon. Better results may be expected in relapsers, but larger studies are necessary.

AB - Background: Up to 80% of hepatitis C patients are refractory to treatment with interferon-α. These patients are not likely to benefit from higher dosages or longer duration of interferon alone. The addition of ribavirin has been shown to improve the response rate in patients resistant to a previous course of interferon-α alone. Aim: To evaluate whether a sustained hepatitis C virus (HCV) RNA response could be obtained with combination therapy of interferon-α and ribavirin in patients who did not respond to or relapsed after a standard interferon-α treatment. Methods: A total of 73 patients, 59 non-responders and 14 relapsers after interferon-α alone, were treated with a combination of ribavirin (1000-1200 mg/day) and interferon-α (3 MU three times a week) for 24 weeks. Alanine aminotransferase levels and HCV RNA were checked for 24 weeks after completion of therapy. Results: At the end of the combination therapy, 36 patients (49%) showed alanine aminotransferase normalization and in 20 patients (27%), HCV RNA was undetectable in serum. At the end of the 24 weeks follow-up period, only 12 patients (16%) had a sustained response with serum negativity of HCV RNA. This response was significantly higher in relapsers than in non-responders: five (36%) vs. seven (12%) patients (P = 0.03), respectively. Adverse effects were restricted to flu-like symptoms and moderate haemolytic anaemia. Conclusions: Combination of interferon-α and ribavirin is quite limited, both in scope and efficacy, in HCV patients who had a non-response to monotherapy with interferon. Better results may be expected in relapsers, but larger studies are necessary.

UR - http://www.scopus.com/inward/record.url?scp=0035181928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035181928&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.2001.00893.x

DO - 10.1046/j.1365-2036.2001.00893.x

M3 - Article

C2 - 11136286

AN - SCOPUS:0035181928

VL - 15

SP - 129

EP - 135

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 1

ER -